Fulvestrant-induced toxic epidermal necrolysis

AUTOR(ES)

Morales-Conde, Macarena

FONTE

An. Bras. Dermatol.

DATA DE PUBLICAÇÃO

09/05/2019

RESUMO

Abstract Toxic epidermal necrolysis is a condition with massive keratinocyte apoptosis, and it is associated with high mortality rates. Fulvestrant, an estrogen receptor antagonist, is indicated in the treatment of estrogen receptor-positive metastatic breast cancer in postmenopausal women. To our knowledge, this is the first described case of toxic epidermal necrolysis due to fulvestrant. A 56-year-old woman received 500 mg of intramuscular fulvestrant monthly for metastatic ductal carcinoma of the breast. Five days after the first dose, the patient presented with a maculopapular rash that evolved to blisters, and a detachment of the epidermis in over 30% of the total body surface area. Histological analysis was compatible with toxic epidermal necrolysis. Fulvestrant was discontinued, topical management and supportive care were initiated.

Documentos Relacionados

• Vandetanib induced phototoxic reaction progressed to toxic epidermal necrolysis
• Early pathological features of the cornea in toxic epidermal necrolysis
• Vancomycin-associated linear IgA disease mimicking toxic epidermal necrolysis
• Bronchial obstruction due to respiratory mucosal sloughing in toxic epidermal necrolysis.
• Improved burn center survival of patients with toxic epidermal necrolysis managed without corticosteroids.